Business Wire

NY-TAKTILE

18.5.2023 21:47:29 CEST | Business Wire | Press release

Share
Taktile Launches Data Marketplace with Leading Data Providers to Empower Lenders

Taktile, the leading automated decisioning platform, announced the launch of its Data Marketplace as part of its mission to revolutionize how fintechs and banks harness data to make decisions.

The Taktile Data Marketplace is a one-stop ecosystem of leading data providers that enables customers to easily access a global collection of traditional credit, identity, fraud, accounting, open banking, and alternative data sources. By leveraging these data sources, Taktile customers can refine their credit policies and automated decision flows to better identify the right customers and make smarter, more accurate decisions that support profitable growth.

Supported data integrations include: Codat, CRS, NovaCredit, Boniversum, credolab, LexisNexis, Experian, Transunion, Equifax, Creditreform and Belvo.

“Identifying the right data sources for your customer segment has never been more important, but building data integrations in-house is often painful, time-consuming, and resource-intensive,” explained Taktile Co-Founder and CEO Maik Taro Wehmeyer. “Our Data Marketplace makes it easy for risk experts to experiment with various data sources so they can focus on improving their decision accuracy rather than on building integrations.”

On Taktile’s low-code platform, fintechs and traditional financial institutions can easily add new data sources from around the world in minutes through using Taktile’s pre-built integrations that support both B2B as well as B2C use cases. In addition, Taktile already offers functionality today that enables customers to easily connect to any modern third-party API so that users are not constrained by the current offering of off-the-shelf integrations.

The obtained data is well-structured and organized, making it easy to glean aggregate insights, build custom metrics, and identify the right KPIs that take decision accuracy to the next level. Users can also simulate decision outcomes before setting new decision strategies live, empowering them to make informed decisions based on real evidence not speculation.

At a time when profitability is top of mind for fintechs and financial institutions, simplifying data integrations is a powerful advantage. Through rapid experimentation, Taktile customers can uncover the best data sources for their target population and ultimately increase acceptance rates, lower default rates, and offer competitive risk-based pricing–all without requiring any engineering resources.

“In a challenging market, it is lenders' ability to harness data to build the most comprehensive view of their borrowers that gives them the edge,” said Phil Low, Head of Partnerships at Codat. "Now that Codat’s universal API is part of Taktile’s Data Marketplace, Taktile customers can incorporate data from any major accounting, open banking or commerce system into their decisioning engine in a few simple steps. In other words, obtaining that edge just got a lot simpler."

The launch of the Data Marketplace reflects Taktile's commitment to innovation and its ongoing efforts to provide customers with the tools they need to succeed in today's rapidly changing business environment. As part of this commitment, Taktile will rapidly add new global data partners every month and expects to triple the number of providers by the end of the year.

About Taktile

Taktile is a rapidly-growing automated decisioning platform that is revolutionizing how companies harness data to steer their business. Taktile’s low-code platform allows companies to easily build, run and evaluate automated decision flows without requiring developers to write complex code. In a world increasingly run on automated decisions, Taktile makes it easy for credit and data teams to build more accurate decision flows, adapt to change quickly, and, ultimately, improve outcomes. Founded in 2020, Taktile has offices in New York, London and Berlin and is backed by leading VCs, including Index Ventures, Tiger Global, and Y Combinator.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005114/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye